PHIA Stock Analysis: Koninklijke Philips | AS
Medical Devices | AS, Netherlands | Market Cap: 23.077m EUR | 12M Return: 2.2% | NL0000009538 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 38.8M
EPS Trend: 47.7%
Qual. Beats: 1
Rev. Trend: -95.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Koninklijke Philips N.V. (PHIA) is a Dutch health technology company founded in 1891 and headquartered in Amsterdam. It operates through three segments: Diagnosis & Treatment (covering diagnostic imaging such as ultrasound, MRI, CT, and X-ray, as well as image-guided therapy systems), Connected Care (monitoring, enterprise informatics, and sleep and respiratory care), and Personal Health (consumer health products). The company is active in North America, Greater China, and other international markets, and maintains a strategic alliance with WellSpan Health focused on advanced imaging and diagnostics.
The company was renamed from Koninklijke Philips Electronics N.V. to its current name in May 2013, reflecting its strategic shift away from consumer electronics and toward health technology. The medical equipment industry in which Philips operates is characterized by high regulatory barriers (FDA, CE marking), long product development cycles, and significant ongoing R&D investment, with demand typically driven by hospital capital expenditure, aging populations, and the digitization of healthcare delivery.
- Respironics CPAP recall settlement clears multi-year legal overhang
- Diagnostic Imaging orders accelerate, boosting Diagnosis & Treatment segment revenue
- China healthcare spending weakness pressures emerging markets revenue growth
| Net Income: 1.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 5.46 > 1.0 |
| NWC/Revenue: 10.80% < 20% (prev 10.43%; Δ 0.37% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.28b > Net Income 1.11b |
| Net Debt (6.64b) to EBITDA (3.06b): 2.17 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (968.6m) vs 12m ago 1.24% < -2% |
| Gross Margin: 45.93% > 18% (prev 43.85%; Δ 2.08% > 0.5%) |
| Asset Turnover: 66.56% > 50% (prev 67.69%; Δ -1.13% > 0%) |
| Interest Coverage Ratio: 5.32 > 6 (EBIT TTM 1.83b / Interest Expense TTM 344.0m) |
| A: 0.07 (Total Current Assets 9.33b - Total Current Liabilities 7.42b) / Total Assets 26.7b |
| B: 0.12 (Retained Earnings 3.18b / Total Assets 26.7b) |
| C: 0.07 (EBIT TTM 1.83b / Avg Total Assets 26.5b) |
| D: 0.75 (Book Value of Equity 11.4b / Total Liabilities 15.2b) |
| Altman-Z'' = 2.11 = BBB |
| DSRI: 1.09 (Receivables 3.60b/3.33b, Revenue 17.7b/17.9b) |
| GMI: 0.95 (GM 43.85% / 45.93%) |
| AQI: 1.00 (AQ_t 0.57 / AQ_t-1 0.57) |
| SGI: 0.99 (Revenue 17.7b / 17.9b) |
| TATA: -0.04 (NI 1.11b - CFO 2.28b) / TA 26.7b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of August 26, 2026, the stock is trading at EUR 23.45 with a total of 698,746 shares traded. Over the past week, the price has changed by -0.17%, over one month by -0.34%, over three months by -1.47% and over the past year by +2.15%.
Current recommended Stop Loss: 22.60 (which is 3.6% or 1.7 ATR below the current price).
Koninklijke Philips has no consensus analysts rating.
P/E Trailing = 20.7105
P/E Forward = 14.9701
P/S = 1.3064
P/B = 2.0262
P/EG = 0.8912
Revenue TTM = 17.7b EUR
EBIT TTM = 1.83b EUR
EBITDA TTM = 3.06b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.43b EUR (from shortLongTermDebtTotal, last quarter) + Leases 964.0m
Net Debt = 6.64b EUR (calculated: Debt 8.43b - CCE 1.79b)
Enterprise Value = 29.7b EUR (23.1b + Debt 8.43b - CCE 1.79b)
Interest Coverage Ratio = 5.32 (Ebit TTM 1.83b / Interest Expense TTM 344.0m)
EV/FCF = 15.63x (Enterprise Value 29.7b / FCF TTM 1.90b)
FCF Yield = 6.40% (FCF TTM 1.90b / Enterprise Value 29.7b)
FCF Margin = 10.76% (FCF TTM 1.90b / Revenue TTM 17.7b)
Net Margin = 6.31% (Net Income TTM 1.11b / Revenue TTM 17.7b)
Gross Margin = 45.93% ((Revenue TTM 17.7b - Cost of Revenue TTM 9.55b) / Revenue TTM)
Gross Margin QoQ = 49.31% (prev 45.20%)
Tobins Q-Ratio = 1.11 (Enterprise Value 29.7b / Total Assets 26.7b)
Interest Expense / Debt = 4.08% (Interest Expense 344.0m / Debt 8.43b)
Taxrate = 24.64% (364.0m / 1.48b)
NOPAT = 1.38b (EBIT 1.83b * (1 - 24.64%))
Current Ratio = 1.26 (Total Current Assets 9.33b / Total Current Liabilities 7.42b)
Debt / Equity = 0.74 (Debt 8.43b / totalStockholderEquity, last quarter 11.4b)
Debt / EBITDA = 2.17 (Net Debt 6.64b / EBITDA 3.06b)
Debt / FCF = 3.49 (Net Debt 6.64b / FCF TTM 1.90b)
Total Stockholder Equity = 11.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 1.11b / Total Assets 26.7b)
RoE = 10.05% (Net Income TTM 1.11b / Total Stockholder Equity 11.1b)
RoCE = 10.51% (EBIT 1.83b / Capital Employed (Equity 11.1b + L.T.Debt 6.32b))
RoIC = 7.05% (NOPAT 1.38b / Invested Capital 19.5b)
WACC = 6.54% (E(23.1b)/V(31.5b) * Re(7.81%) + D(8.43b)/V(31.5b) * Rd(4.08%) * (1-Tc(0.25)))
Discount Rate = 7.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.94 | Cagr: 1.95%
[DCF] Terminal Value 77.97% ; FCFF base≈1.32b ; Y1≈1.51b ; Y5≈2.22b
[DCF] Fair Price = 27.39 (EV 33.4b - Net Debt 6.64b = Equity 26.8b / Shares 977.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 47.74 | EPS CAGR: 152.6% | SUE: 1.74 | # QB: 1
Revenue Correlation: -95.13 | Revenue CAGR: -1.45% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.34 | Chg30d=-10.73% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=1.63 | Chg30d=+6.58% | Revisions=+71% | GrowthEPS=+4.7% | GrowthRev=+0.5%
EPS next Year (2027-12-31): EPS=1.68 | Chg30d=-1.57% | Revisions=-31% | GrowthEPS=+3.1% | GrowthRev=+4.4%
[Analyst] Revisions Ratio: +12% (up=17, down=13)